Instead, treatment begins at 0.25 mg weekly and increases in small increments every four weeks until reaching 2.4 mg weekly
(NEJM 2007, n=412) documented a reduction of -15.2% in visceral adipose tissue, +81% in IGF-1, -50 mg/dL in triglycerides and -0.31 in the cholesterol/HDL ratio at 26 weeks (2 mg SC/day vs placebo)
But if youve noticed more headaches since beginning treatment, youre not alone
Although there are these limitations, these results suggest that the possibility of combination therapy with resmetirom and semaglutide, may be beneficial for MASH treatment and improve MASH treatment outcomes
Additionally, there was variation in the quality of included studies as the risk of bias, methodological rigor, and data integrity were not well tracked or standardized across the available articles
Colditz, MD, Meir J